YM BioSciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From YM BioSciences Inc.
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
The resurgence of the pandemic during the fourth quarter of 2020 led to slowdown in elective procedures, negatively impacting sales of the four big ortho players.
Zimmer Biomet’s CEO Bryan Hanson expects the spin-off will help streamline the company and optimize resources for innovation.
- Other Names / Subsidiaries
- Cytopia Limited